Yet another update, around January 25, 2025, by Amal Thommil:
##############################
ORIGINAL FOLLOWS
##############################
Via Linked-In, Amal Thommil of DeciBio reports on the status of MRD coverage.
Take-home lesson - the top three insurers providing MRD coverage are MolDx, MolDx, and MolDx. (Old joke).
Find his Linked In post here:
Here's a rough screen shot; see original above.
I believe the Louisiana BCBS coverage is related to a state biomarker bill. Note that the circles denote tissue type by color, and name-brand by name. (E.g. yellow circle = bladder = Natera).
See also a follow-on post by Amal [Jan12], here. See comments by Amal on Natera using WGS rather than exome for MRD [Jan 17] here.
### NATERA
During JP Morgan 2025, Naterea announces a webinar on its "Innovation Roadmap."
See Linked In essay by Julie Deschenes here. Go direct to January 15 webinar info here. Go driect to Natera/Investors.
### NATURE REV CLIN ONC / Normanno 2025
In January 2025, a review on whether MRD is ready for use in NSCLC, or not. Note that some KOL's may be very gung ho on MRD use, and some companies and MOLDX are fully on board. However, if your horizon scan includes journals like Nature Reviews Clinical Oncology, you'll see more circumspect discussions at this point in time. Normanno et al. This also comports with the timely updated graphic from Decibio, which shows both progress, and, a relatively small, countable, list of tests and specific indications.
https://www.nature.com/articles/s41571-024-00985-w
- In this Review, we summarize the increasing evidence suggesting that ctDNA has potential clinical applications in the management of patients with early stage and locally advanced NSCLC. In those with early stage NSCLC, detection of ctDNA before and/or after surgery is associated with a greater risk of disease recurrence. Longitudinal monitoring after surgery can further increase the prognostic value of ctDNA testing and enables detection of disease recurrence earlier than the assessment of clinical or radiological progression.
- In patients with locally advanced NSCLC, the detection of ctDNA after chemoradiotherapy is also associated with a greater risk of disease progression.
- Owing to the limited number of patients enrolled and the different technologies used for ctDNA testing in most of the clinical studies performed thus far, their results are not sufficient to currently support the routine clinical use of ctDNA monitoring in patients with early stage or locally advanced NSCLC.
- Therefore, we discuss the need for interventional studies to provide evidence for implementing ctDNA testing in this setting.
